PRESS

San Francisco, December 4, 2024 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced the filing of a new international patent application with the potential of significantly improving administration of the company’s lead drug candidate Dutogliptin. Recardio filed a new international patent application for its novel formulation process Recardio has filed a new international PCT application, publ

San Francisco, September 10, 2024 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the LSX World Congress 2024 in Boston. LSX World Congress 2024 in Boston The congress is an international event that gathers leaders from biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique pl

San Francisco, June 3, 2024 - Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the BIO International Convention 2024 in San Diego. BIO International 2024 in San Diego The conference is held annually and brings together the most innovative thinkers and leaders in biotechnology to provide opportunities through global partnerships, collaboration and thought l